Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Breast Cancer

38 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCBRE1366

09/03/2014

Predictors of Post-Mastectomy Local-Regional Recurrence and Distant Metastases

Basic Science

VICCBRE1445

04/21/2014

Optical Imaging of Breast Tumors

Basic Science

VICCBRE1101

02/28/2011

A Retrospective Evaluation of Clinical Breast MRIs in Patients with Localized Breast Cancer

Basic Science

VICCBRE0767

06/11/2008

Predicting Cardiac Effects of Breast Cancer Therapy

Basic Science

VICCBRE03103

01/22/2004

Breast Tissue/Body Fluids Repository (SPORE)

Basic Science

VCCBRE0057

10/27/2000

Nashville Breast Health Study

Diagnostic

ACRINBRE6702

06/11/2014

A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer

Diagnostic

VICCBRE1277

01/01/2013

Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer

Diagnostic

VICCBRE09108

10/13/2010

PET/CT Evaluation of Treatment Response in Breast Cancer

Diagnostic

VICCBRE0588

03/07/2006

MRI Evaluation Of Breast Tumor Growth And Treatment Response (SPORE)

Other

VICCSUPP1224

11/19/2012

Osteonecrosis of the Jaw Case (ONJ) Registry

Other

ECOGBREE2Z04-M

06/11/2008

Quality of LIfe in Younger Breast Cancer Survivors

Other

CTSUBREC70301-M

06/11/2007

Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

Other

VICCBRE0704

02/21/2007

Developing In-Vivo Models of Human Breast Cancer

Supportive Care

VICCBRE1438

06/19/2014

A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measurement in the Prevention of Lymphedema following Locoregional Treatment for Breast Cancer

Supportive Care

VICCREACH1341

09/05/2013

Using a Tailored Navigation Intervention to Prepare Patients and Their Support Person for the Journey at Time of Cancer Diagnosis and at Transition into Survivorship

Treatment

VICCBRE1358

09/15/2014

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

Treatment

VICCBRE1440

08/21/2014

A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Treatment

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Treatment

VICCBRE1411

05/22/2014

A Phase 1b Study of LY2835219 in Combination with Endocrine Therapies for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Treatment

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment

VICCBRE1390

04/23/2014

A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone-Receptor Positive, HER2-negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease

Treatment

VICCPHI1394

04/17/2014

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Treatment

VICCBRE1385

03/03/2014

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients with Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal

Treatment

VICCPHI1359

12/03/2013

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Treatment

VICCBRE1287

09/23/2013

A Phase Ib/II Trial of GDC-0941 (a PI3K inhibitor) in combination with Cisplatin in patients with androgen receptor negative Triple Negative Metastatic Breast Cancer

Treatment

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Treatment

VICCBRE1304

06/04/2013

A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Treatment

VICCBRE1298

04/19/2013

A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft? Axxent? eBx System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer

Treatment

VICCBRE12101

04/04/2013

A Phase Ib Trial of BYL719 (an a-Specific PI3K Inhibitor) in Combination with Endocrine Therapy in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Treatment

VICCBREP12116

03/25/2013

An Open-Label, Phase I/IIa Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Treatment

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Treatment

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Treatment

CTSUBRENCCTGMA32-M

04/23/2012

A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Treatment

CTSUBRES1007-M

05/25/2011

Phase III randomized trial of standard adjuvant endocrine therapy +/- chemo in patients with 1-3 positive nodes, hormone receptor positive and Her2 negative breast cancer with recurrence score (RS) of 25 or less

Treatment

CTSUBREC40603-M

12/07/2010

Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer